Related Experiment Video
Updated: Jul 2, 2025
06:19
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
820
Mortality risk after COVID-19 vaccination: A self-controlled case series study
Stanley Xu1, Lina S Sy2, Vennis Hong2
1Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States.
Vaccine
|February 22, 2024
Summary
COVID-19 vaccination showed no increased risk of death from any cause or cardiac events. This study analyzed mortality following primary COVID-19 vaccine series in the US, finding no significant safety concerns.
Area of Science:
- Epidemiology
- Vaccine Safety Research
- Public Health
Background:
- Previous studies on COVID-19 vaccination and mortality risk had potential residual confounding.
- A modified self-controlled case series (SCCS) design was employed to mitigate bias.
- The study focused on non-COVID-19 mortality, all-cause mortality, and specific cardiac-related death outcomes.
Purpose of the Study:
- To assess the risk of non-COVID-19 mortality after primary COVID-19 vaccination.
- To evaluate the risk of all-cause mortality following COVID-19 vaccination.
- To examine the risk of four cardiac-related death outcomes post-COVID-19 vaccination.
Main Methods:
- Utilized a modified SCCS design analyzing deaths from December 2020 to August 2021 across eight Vaccine Safety Datalink sites.
- Calculated relative incidences (RI) for various mortality outcomes after primary COVID-19 vaccine series (Pfizer-BioNTech, Moderna, Janssen).
- Adjusted for seasonality using calendar month and included unvaccinated individuals in analyses, with primary (28-day) and secondary (14-day) risk intervals.
Main Results:
- For Pfizer-BioNTech and Moderna vaccines, relative incidences for all-cause and non-COVID-19 mortality were below 1, with confidence intervals excluding 1.
- For Moderna, two cardiac-related mortality estimates had confidence intervals including 1 (RI=0.78-0.80) 14 days post-second dose in specific subgroups.
- For Janssen vaccine, relative incidences for cardiac-related deaths ranged from 0.68-0.98, with confidence intervals including 1.
Conclusions:
- The modified SCCS design, accounting for temporal trends, found no increased risk of non-COVID-19 mortality or all-cause mortality after primary COVID-19 vaccination.
- No increased risk was identified for four specific cardiac-related death outcomes among recipients of the three main US COVID-19 vaccines.
- The findings support the safety of primary COVID-19 vaccine series regarding mortality risk.
Related Concept Videos
01:51Vaccinations
44.5K
Overview
44.5K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
01:20Actuarial Approach
78
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
78
01:21Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
01:30Cancer Vaccines
367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367
01:15Assumptions of Survival Analysis
127
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
127